CoChat

Update in Testosterone Therapy for Men (CME)

Corona, Giovanni, Rastrelli, Giulia, Forti, Gianni, Maggi, Mario · 2011 · The Journal of Sexual Medicine
Cited by 124

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Introduction: Male hypogonadism is a condition characterized by inadequate testicular production of sex steroids and sperms; however, the term is more commonly used to identify testosterone (T) deficiency. When fertility is not desired, T replacement therapy (TRT) is the gold standard. Aim: To review the pathogenesis of male hypogonadism and the available preparations for TRT, along with the main clinical outcomes. Methods: A systematic search of published evidence was performed using Medline (1969 to September 2010). Data from a consecutive series of subjects attending our Andrology Unit were also provided to stress the clinical correlates of low T. Inventories available for detecting hypogonadism (including ANDROTEST) were overviewed. Main Outcome Measures: The most important studies regarding the pathogenesis of male hypogonadism and the preparations for its treatment were reviewed. To review TRT outcomes, only meta-analytic studies were considered. Results: The goals of TRT are to alleviate clinical symptoms and to restore serum T levels to the mid-normal range, without significant side effects or safety concerns. Different T formulations have been approved. TRT is associated with a reduction of fat mass, an increase of lean mass, and a possible positive effect on lipid profile and glycometabolic control. Bone density and depressive symptoms are improved by TRT, while effects on cardiovascular risk and frailty are more controversial. No increase of prostate cancer and prostate-related problems has been reported so far. TRT, alone or in combination with phosphodiesterase type 5 inhibitors, is considered the first-line therapy in hypogonadal subjects with erectile dysfunction. Conclusions: T deficiency is highly prevalent in the aging male and represents a sign of physical and sexual frailty. The significance of low T in elderly men has yet to be completely clarified. Large, prospective intervention trials will help solve this dilemma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1743-6109.2010.02200.x

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 34

  1. Petak, 2002, American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update, Endocr Pract, 8, 440, 10.4158/EP.8.6.439 · DOI · Paper page
  2. Corona, 2010, The role of testosterone in erectile dysfunction, Nat Rev Urol, 7, 46, 10.1038/nrurol.2009.235 · DOI · Paper page
  3. Morelli, 2007, Which patients with sexual dysfunction are suitable for testosterone replacement therapy?, J Endocrinol Invest, 30, 880, 10.1007/BF03349232 · DOI
  4. Maggi, 2009, Endocrinology of male sexual function, 61
  5. Corona, 2009, Recognizing late-onset hypogonadism: A difficult task for sexual health care, J Mens Health Gend, 6, 205
  6. van den Beld, 2000, Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men, J Clin Endocrinol Metab, 85, 3276
  7. Gray, 1991, Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study, J Clin Endocrinol Metab, 73, 1016, 10.1210/jcem-73-5-1016 · DOI · Paper page
  8. Orwoll, 2006, Testosterone and estradiol among older men, J Clin Endocrinol Metab, 91, 1336, 10.1210/jc.2005-1830 · DOI · Paper page
  9. Mikhail, 2006, Does testosterone have a role in erectile function?, Am J Med, 119, 373, 10.1016/j.amjmed.2005.07.042 · DOI
  10. Traish, 2009, The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction, J Androl, 30, 10, 10.2164/jandrol.108.005215 · DOI · Paper page
  11. Heinemann, 2004, Can results of the Aging Males’ Symptoms (AMS) scale predict those of screening scales for androgen deficiency?, Aging Male, 7, 211, 10.1080/13685530400004223 · DOI · Paper page
  12. Morley, 2006, Comparison of screening questionnaires for the diagnosis of hypogonadism, Maturitas, 53, 424, 10.1016/j.maturitas.2005.07.004 · DOI · Paper page
  13. Simmer, 1961, Arnold Adolph Berthold (1803–1861) Zur Erinnerung an den hundertsten Todestag des Begrunders der experimentellen, Endokrinologie Dtsch Med Wschr, 86, 2186, 10.1055/s-0028-1113073 · doi:10.1055/s-0028-1113073
  14. Qoubaitary, 2005, Advances in male hormone substitution therapy, Expert Opin Pharmacother, 6, 1493, 10.1517/14656566.6.9.1493 · DOI
  15. Seftel, 2007, Testosterone replacement therapy for male hypogonadism: Part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents, Int J Impot Res, 19, 2, 10.1038/sj.ijir.3901366 · DOI
  16. Edelstein, 2007, The latest options and future agents for treating male hypogonadism, Expert Opin Pharmacother, 8, 2991, 10.1517/14656566.8.17.2991 · DOI
  17. Pfeil, 2008, Current and future testosterone delivery systems for treatment of the hypogonadal male, Expert Opin Drug Deliv, 5, 471, 10.1517/17425247.5.4.471 · DOI
  18. Behre, 2004, Pharmacology of testosterone preparations, 405
  19. Snyder, 1980, Treatment of male hypogonadism with testosterone enanthate, J Clin Endocrinol Metab, 51, 1335, 10.1210/jcem-51-6-1335 · DOI · Paper page
  20. Plymate, 1994, Hypogonadism, Endocrinol Metab Clin North Am, 23, 749, 10.1016/S0889-8529(18)30065-3 · DOI
  21. Matsumoto, 1994, Hormonal therapy of male hypogonadism, Endocrinol Metab Clin North Am, 23, 857, 10.1016/S0889-8529(18)30072-0 · DOI
  22. Jain, 2000, Testosterone supplementation for erectile dysfunction: Results of a meta-analysis, J Urol, 164, 371, 10.1016/S0022-5347(05)67363-6 · DOI · Paper page
  23. Tsertsvadze, 2009, Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: A systematic review and meta-analysis, Ann Intern Med, 151, 650, 10.7326/0003-4819-151-9-200911030-00150 · DOI · Paper page
  24. Corona, 2010, Androgen regulation of prostate cancer: Where are we now?, J Endocrinol Invest
  25. Endogenous Hormones and Prostate Cancer Collaborative Group, 2008, Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies, J Natl Cancer Inst, 100, 170, 10.1093/jnci/djm323 · DOI · Paper page
  26. Morgentaler, 2009, Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth, Eur Urol, 55, 310, 10.1016/j.eururo.2008.09.024 · DOI · Paper page
  27. Corona, 2010, The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction, J Sex Med, 7, 284, 10.1111/j.1743-6109.2009.01549.x · DOI · Paper page
  28. Isidori, 2005, Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis, Clin Endocrinol (Oxf), 63, 280, 10.1111/j.1365-2265.2005.02339.x · DOI · Paper page
  29. Corona, 2010, Testosterone, cardiovascular disease and the metabolic sindrome, Best Pract Res Clin Endocrinol Metab
  30. Jones, 2010, Testosterone deficiency: A risk factor for cardiovascular disease?, Trends Endocrinol Metab, 21, 496, 10.1016/j.tem.2010.03.002 · DOI · Paper page
  31. Haddad, 2007, Testosterone and cardiovascular risk in men: A systematic review and meta-analysis of randomized placebo-controlled trials, Mayo Clin Proc, 82, 29, 10.1016/S0025-6196(11)60964-6 · DOI · Paper page
  32. Aversa, 2010, Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle aged men with late-onset hypogonadism and metabolic syndrome: Results from a 24-month, randomized, double-blind, placebo-controlled study, J Sex Med, 7, 3495, 10.1111/j.1743-6109.2010.01931.x · DOI · Paper page
  33. Iervasi, 2003, Low-T3 syndrome: A strong prognostic predictor of death in patients with heart disease, Circulation, 107, 708, 10.1161/01.CIR.0000048124.64204.3F · DOI · Paper page
  34. Bartalena, 1998, Role of cytokines in the pathogenesis of the euthyroid sick syndrome, Eur J Endocrinol, 138, 603, 10.1530/eje.0.1380603 · DOI

Cited by

See all 124

Metadata

Authors
Corona, G., Rastrelli, G., Forti, G., & Maggi, M.
Venue
The Journal of Sexual Medicine
Published
2011-03-01
Volume
8
Issue
3
Pages
639-654
ISSN
  • 1743-6095 (ISSN-L)
  • 1743-6109
OpenAlex
W2152493522
Cited by
124
References
30
FWCI
15.77
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Update in Testosterone Therapy for Men (CME). https://app.cochat.ai/papers/10.1111/j.1743-6109.2010.02200.x
The paper
Corona, G., Rastrelli, G., Forti, G., & Maggi, M. (2011). Update in Testosterone Therapy for Men (CME). The Journal of Sexual Medicine. https://doi.org/10.1111/j.1743-6109.2010.02200.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.